Gross Product Revenues was Exelixis’s largest product and service line in fiscal 2026, bringing in $3.01B of $2.32B (130%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2020 | FY 2021 | FY 2021 | FY 2022 | FY 2023 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Product Revenues | $2.27B | $2.52B | $3.01B | |||||||
| License Revenues | $178.64M | $349.24M | $214.38M | |||||||
| License | — | — | — | |||||||
| Cabometyx | — | — | — | |||||||
| Cometriq | — | — | — | |||||||
| Collaboration Services Revenues | $22.69M | $10.06M | -$17.05M | |||||||
| Research & Development Service Revenues | — | — | — | |||||||
| Other Collaboration Revenues | — | — | — | |||||||
| Discounts & Allowances | -$643.65M | -$708.85M | -$889.00M | |||||||
| Total | $1.83B | $2.17B | $2.32B |
Exelixis brought in $2.32B from its four product and service lines in fiscal 2026, the year ended January 2, 2026. That was up 7.0% from $2.17B in fiscal 2025. Gross Product Revenues was the largest at $3.01B (129.8%), ahead of License Revenues at $214.38M (9.2%).
Compared with fiscal 2025, Gross Product Revenues grew 19.6% to $3.01B, while License Revenues fell 38.6% to $214.38M. From fiscal 2023 to 2026, combined revenue from these lines grew from $1.83B to $2.32B, a compound annual growth rate of 8.2%. Gross Product Revenues' share of the total rose from 124.2% to 129.8%.
The total is net of Collaboration Services Revenues, which took $17.05M off revenue in fiscal 2026.
U.S was Exelixis’s largest region in fiscal 2026, bringing in $2.14B of $2.32B (92%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2020 | FY 2021 | FY 2021 | FY 2022 | FY 2023 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $1.65B | $1.82B | $2.14B | |||||||
| Europe | $144.97M | $318.63M | $154.17M | |||||||
| Japan | $39.49M | $27.08M | $25.59M | |||||||
| Rest Of The World | — | — | — | |||||||
| Total | $1.83B | $2.17B | $2.32B |
Exelixis brought in $2.32B from its three regions in fiscal 2026, the year ended January 2, 2026. That was up 7.0% from $2.17B in fiscal 2025. U.S was the largest at $2.14B (92.3%), ahead of Europe at $154.17M (6.6%) and Japan at $25.59M (1.1%).
Compared with fiscal 2025, U.S grew 17.4% to $2.14B, while Europe fell 51.6% to $154.17M. From fiscal 2023 to 2026, combined revenue from these regions grew from $1.83B to $2.32B, a compound annual growth rate of 8.2%. U.S's share of the total rose from 89.9% to 92.3%.
Diplomat Specialty Pharmacy was Exelixis’s largest revenue line in fiscal 2016, bringing in $63.83M of $191.45M (33%).
| Customer | FY 2016 |
|---|---|
| Diplomat Specialty Pharmacy | $63.83M |
| Others, Individually Less Than 10% Of Total Revenues For All Periods Presented | $46.86M |
| Ipsen | $33.25M |
| Caremark L.L.C | $17.75M |
| Accredo Health, Incorporated | $16.63M |
| Affiliates Of Mckesson Corporation | $13.14M |
| Total | $191.45M |
Exelixis brought in $191.45M from its six revenue lines in fiscal 2016, the year ended December 30, 2016. Diplomat Specialty Pharmacy was the largest at $63.83M (33.3%), ahead of Others, Individually Less Than 10% Of Total Revenues For All Periods Presented at $46.86M (24.5%) and Ipsen at $33.25M (17.4%). The other three revenue lines brought in $47.52M combined.
Exelixis (EXEL) reports its revenue by product and service, by geography and by customer. In fiscal 2026, Gross Product Revenues was its largest product and service line, bringing in $3.01B (129.8% of the total), followed by License Revenues at $214.38M (9.2%).
Gross Product Revenues was Exelixis' largest product and service line in fiscal 2026, bringing in $3.01B, or 129.8% of the $2.32B total across its four product and service lines.
U.S was Exelixis' largest region in fiscal 2026, bringing in $2.14B, or 92.3% of the $2.32B total across its three regions.
Diplomat Specialty Pharmacy was Exelixis' largest revenue line in fiscal 2016, bringing in $63.83M, or 33.3% of the $191.45M total across its six revenue lines.
Gross Product Revenues grew faster than License Revenues in fiscal 2026, up 19.6% from $2.52B to $3.01B. License Revenues fell 38.6% to $214.38M.
Every figure comes from Exelixis' annual financial filings, as reported. Each line keeps the name Exelixis gives it, and years follow its fiscal calendar.
Exelixis' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.